ArticleLeukemia2014
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.
Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2016Guideline
- Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus.Molecular therapy. Oncology · 2025Article
- Ruxolitinib and Hepatitis-B Virus Reactivation: A Clinical Concern Requiring Prophylactic Management.Pakistan journal of medical sciences · 2025Article
- Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib.EJHaem · 2025Article
- Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib.World journal of hepatology · 2023Review
- Tofacitinib treatment of rheumatoid arthritis increases senescent T cell frequency in patients and limits T cell function in vitro.European journal of immunology · 2023Article
- Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations-10 Children and Review of the Literature.Journal of clinical immunology · 2022Review
- Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.International journal of hematology · 2022Review
- The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy.British journal of haematology · 2022Review
- Adverse Effects of Immunosuppression: Infections.Handbook of experimental pharmacology · 2022Article
- Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.Cancers · 2021Review
- Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.Bone marrow transplantation · 2021Review
- Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors.Frontiers in immunology · 2021Review
- Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations.Cancers · 2020Review
- The CoV-2 outbreak: how hematologists could help to fight Covid-19.Pharmacological research · 2020Article
- The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.Leukemia · 2020Article
- Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?Annals of hematology · 2020Article
- Immunotherapy in Myeloproliferative Diseases.Cells · 2020Review
- Management of Myelofibrosis: from Diagnosis to New Target Therapies.Current treatment options in oncology · 2020Review
- Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.Infection and drug resistance · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
23929216What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.